Literature DB >> 103841

Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa.

G B Pier, H F Sidberry, J C Sadoff.   

Abstract

A high-molecular-weight alkali-labile polysaccharide (PS) isolated from the slime of immunotype 1 Pseudomonas aeruginosa was tested for its ability to protect mice from lethal challenge with the live, homologous organism. Intraperitoneal (i.p.) injection of 10 to 25 microgram of the PS protected 60 to 70% of the mice against challenge with up to 50 50% lethal dose units. Although single immunization of mice with up to 250 microgram of PS effected protective levels of only 70%, two successive immunizations provided 100% protection. Subcutaneous and intravenous immunization with PS also provided protection to i.p. challenges with immunotype 1 P. aeruginosa, but not to i.p. challenge with immunotype 4 P. aeruginosa. Although lipopolysaccharide (LPS) was found to be more immunogenic than PS in out studies, contamination of the alkali-labile PS with LPS did not account for the protection seen. Alkali treatment (0.1 N NaOH, 37 degrees C, 2 h) of the PS destroyed its protective effectiveness, while similarly treated LPS retained its capacity for inducing immunity in mice. Adsorption and passive protection studies with sera raised to either PS or a mixture of PS and LPS indicated that antibody directed to the alkali-labile PS antigen was capable of contributing to the protection of mice against challenge with P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 103841      PMCID: PMC422244          DOI: 10.1128/iai.22.3.919-925.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  A Clinical Lecture ON A CASE OF BACILLUS PYOCYANEUS PYAEMIA SUCCESSFULLY TREATED BY VACCINE: Delivered at the Bristol General Hospital.

Authors:  E H Groves
Journal:  Br Med J       Date:  1909-05-15

2.  Infections caused by Pseudomonas species in patients with burns and in other surgical patients.

Authors:  B A Pruitt
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

3.  Direct evidence for the presence of lipopolysaccharide components in Pseudomonas ribosomal vaccine.

Authors:  M M Lieberman
Journal:  Infect Immun       Date:  1977-08       Impact factor: 3.441

4.  Pseudomonas aeruginosa vaccine in cancer patients.

Authors:  L S Young; R D Meyer; D Armstrong
Journal:  Ann Intern Med       Date:  1973-10       Impact factor: 25.391

5.  Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: a progress report.

Authors:  M L Tapper; D Armstrong
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

6.  Nosocomial infections due to Pseudomonas.

Authors:  J V Bennett
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

7.  Prevention of pneumococcal infection by immunization with capsular polysaccharides of Streptococcus pneumoniae: current status of polyvalent vaccines.

Authors:  R Austrian
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

8.  Isolation and characterization of a high-molecular-weight polysaccharide from the slime of Pseudomonas aeruginosa.

Authors:  G B Pier; H F Sidberry; S Zolyomi; J C Sadoff
Journal:  Infect Immun       Date:  1978-12       Impact factor: 3.441

9.  Analysis of parameters affecting the solid phase radioimmunoassay quantitation of antibody to meningococcal antigens.

Authors:  W D Zollinger; J M Dalrymple; M S Artenstein
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

10.  A new polyvalent Pseudomonas vaccine.

Authors:  J M Miler; J F Spilsbury; R J Jones; E A Roe; E J Lowbury
Journal:  J Med Microbiol       Date:  1977-02       Impact factor: 2.472

View more
  32 in total

1.  Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine.

Authors:  S J Cryz; E Furer; J C Sadoff; R Germanier
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

2.  Preparation and characterization of a nontoxic polysaccharide-protein conjugate that induces active immunity and passively protective antibody against Pseudomonas aeruginosa immunotype 1 in mice.

Authors:  G C Tsay; M S Collins
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

3.  Immunization with Pseudomonas aeruginosa high-molecular-weight polysaccharides prevents death from Pseudomonas burn infections in mice.

Authors:  M Pollack; G B Pier; R K Prescott
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

4.  Role of lipopolysaccharide in virulence of Pseudomonas aeruginosa.

Authors:  S J Cryz; T L Pitt; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

5.  Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice.

Authors:  H E Gilleland; M G Parker; J M Matthews; R D Berg
Journal:  Infect Immun       Date:  1984-04       Impact factor: 3.441

6.  Immunochemical characterization of high-molecular-weight polysaccharide from Fisher immunotype 3 Pseudomonas aeruginosa.

Authors:  G B Pier; M Pollack; M Cohen
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

Review 7.  Cystic fibrosis. Infection and immunity to Pseudomonas.

Authors:  R U Sorensen; R L Waller; J D Klinger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

8.  Immunization with a Pseudomonas aeruginosa 1244 pilin provides O-antigen-specific protection.

Authors:  Joseph Horzempa; Thomas K Held; Alan S Cross; Dana Furst; Mohammed Qutyan; Alice N Neely; Peter Castric
Journal:  Clin Vaccine Immunol       Date:  2008-02-13

9.  Further purification and characterization of high-molecular-weight polysaccharide from Pseudomonas aeruginosa.

Authors:  G B Pier; M Cohen; H Jennings
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

10.  Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.